Alzamend Neuro, Inc.

USD

0.62

	Apr '19	Apr '20	Apr '21	Apr '22	Apr '23
revenue
cost of revenue					23.07K -
gross profit					-23.07K -
selling and marketing expenses				17.65K -	742.60K 4,106.42%
general and administrative expenses	1.31M -	3.35M 156.32%	3.64M 8.54%	7.12M 95.49%	6.68M 6.13%
selling general and administrative expenses	1.31M -	3.35M 156.32%	3.64M 8.54%	7.12M 95.49%	7.42M 4.30%
research and development expenses	3.70M -	1.07M 71.10%	1.31M 22.56%	5.20M 296.83%	7.45M 43.15%
other expenses
cost and expenses	5.01M -	4.42M 11.67%	4.95M 11.93%	12.32M 148.78%	14.87M 20.71%
operating expenses	5.01M -	4.42M 11.67%	4.95M 11.93%	12.32M 148.78%	14.87M 20.71%
interest expense			158.80K -	46.52K 70.70%	7.70K 83.45%
ebitda	-5.01M -	-4.42M 11.67%	-4.95M 11.89%	-12.32M 148.80%	-14.85M 20.55%
operating income	-5.01M -	-4.42M 11.67%	-4.95M 11.93%	-12.32M 148.78%	-14.87M 20.71%
depreciation and amortization	5.01K -	4.42K 11.67%	1.71K 61.44%	3.55K 108.03%	23.07K 549.93%
total other income expenses net	146.39K -	13.93K 90.49%	-94.68K 779.92%	-42.52K 55.09%	-7.70K 81.89%
income before tax	-4.86M -	-4.41M 9.30%	-5.05M 14.43%	-12.36M 144.96%	-14.88M 20.35%
income tax expense	-146.39K -	-13.93K 90.49%	157.10K 1,228.17%	42.52K 72.93%
net income	-4.86M -	-4.40M 9.59%	-5.20M 18.36%	-12.40M 138.38%	-14.88M 19.94%
weighted average shs out	5.69M -	5.69M 0%	4.84M 14.83%	5.94M 22.64%	6.50M 9.45%
weighted average shs out dil	5.69M -	5.69M 0%	4.84M 14.83%	5.94M 22.64%	6.50M 9.45%
eps	-0.86 -	-0.77 10.47%	-1.07 38.96%	-2.09 95.33%	-2.29 9.57%
epsdiluted	-0.86 -	-0.77 10.47%	-1.07 38.96%	-2.09 95.33%	-2.29 9.57%

All numbers in USD (except ratios and percentages)